0000899243-22-031193.txt : 20220915
0000899243-22-031193.hdr.sgml : 20220915
20220915195320
ACCESSION NUMBER: 0000899243-22-031193
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220913
FILED AS OF DATE: 20220915
DATE AS OF CHANGE: 20220915
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Grant Julie Papanek
CENTRAL INDEX KEY: 0001673237
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40431
FILM NUMBER: 221246794
MAIL ADDRESS:
STREET 1: 2765 SAND HILL ROAD
CITY: MENLO PARK
STATE: CA
ZIP: 94025
FORMER NAME:
FORMER CONFORMED NAME: Grant Papanek Julie
DATE OF NAME CHANGE: 20210518
FORMER NAME:
FORMER CONFORMED NAME: Papanek Julie
DATE OF NAME CHANGE: 20160427
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Day One Biopharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001845337
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 832415215
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 395 OYSTER POINT BLVD STE 217
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080-1930
BUSINESS PHONE: 206-913-4300
MAIL ADDRESS:
STREET 1: 395 OYSTER POINT BLVD STE 217
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080-1930
FORMER COMPANY:
FORMER CONFORMED NAME: Day One Biopharmaceuticals Holding Co LLC
DATE OF NAME CHANGE: 20210209
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-09-13
0
0001845337
Day One Biopharmaceuticals, Inc.
DAWN
0001673237
Grant Julie Papanek
395 OYSTER POINT BLVD, SUITE 217
SOUTH SAN FRANCISCO
CA
94080
1
0
0
0
Common Stock
2022-09-13
4
S
0
86644
24.39
D
9577001
I
See Footnote
Common Stock
2022-09-13
4
S
0
1003
25.01
D
9575998
I
See Footnote
Common Stock
2022-09-14
4
S
0
105727
23.68
D
9470271
I
See Footnote
Common Stock
2022-09-14
4
S
0
384
24.29
D
9469887
I
See Footnote
Common Stock
2022-09-15
4
S
0
47967
22.79
D
9421920
I
See Footnote
Common Stock
2022-09-15
4
S
0
3314
23.73
D
9418606
I
See Footnote
Common Stock
439358
I
See Footnote
Common Stock
362
I
See Footnote
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 - $24.99, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Represents shares held by Canaan XI L.P. The Reporting Person is a non-managing member of Canaan Partners XI LLC, the general partner of Canaan XI L.P. The Reporting Person does not have voting or dispositive power over any of the shares held directly by Canaan XI L.P. and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or for any other purpose.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 - $25.06, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.25 - $24.23, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.28 - $24.29, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 - $23.52, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.55 - $24.01, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Act, or for any other purpose.
Represents shares held by The Adam and Julie Grant Revocable Trust dtd October 13, 2017 of which the Reporting Person and her spouse are co-trustees. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Act, or for any other purpose.
/s/ Nancy Levenson, Attorney-in-Fact
2022-09-15